Table 1.
On-going clinical trials for a combination of immune checkpoint inhibitors and radiation.
| NCT number | Institution | Phase | Disease | Intervention | Estimated enrollment | Primary endpoint |
|---|---|---|---|---|---|---|
| NCT03482102 | United States (MGH) | II | Locally advanced/unresectable or metastatic HCC or biliary tract cancer | Tremelimumab + Durvalumab + EBRT | 70 | ORR |
| NCT03203304 | United States (UCh) | I | Unresectable HCC | Nivolumab + SBRT vs nivolumab and ipilimumab + SBRT | 50 | Number of participants with adverse events |
| NCT03316872 | Canada (UHN) | II | HCC progression after sorafenib | Pembrolizumab +SBRT | 30 | ORR |
| NCT04167293 | China (Sun Yatsen University Cancer Center) | II/III | HCC with portal vein invasion | SBRT + sintilimab vs SBRT | 116 | 6-mo PFS |
| NCT03817736 | Hong Kong (Queen Mary Hospital) | II | HCC | TACE/SBRT + ICI | 33 | Number of patients eligible for curative surgical interventions |
| NCT04611165 | South Korea (NCC) | II | HCC with major vascular invasion | Nivolumab + EBRT | 50 | PFS |
| NCT04547452 | China (West China Hospital) | II | Metastatic HCC | SBRT + sintilimab vs sintilimab | 84 | PFS |
| NCT04193696 | China (Guangxi Medical University) | II | Advanced HCC | RT+ anti-PD-1 agent | 39 | ORR |
MGH, Massachusetts General Hospital; HCC, Hepatocellular carcinoma; EBRT, External beam radiotherapy; UCh, University of Chicago; SBRT, Stereotactic body radiotherapy; UHN, University Health Network; PFS, Progression-free survival; TACE, Transcatheter arterial chemoembolization; ICI, Immune checkpoint inhibitor; NCC, National Cancer Center; ORR, Overall response rate; RT, Radiotherapy; PD-L1, Programmed cell death ligand 1.